Lederfolin

Calcium Levofolinate, the active ingredient in Lederfolin, is a folate analog presented as an injectable solution for intravenous use. It is employed to rescue cells from methotrexate toxicity, to enhance the effect of 5‑fluorouracil chemotherapy, and to correct folate deficiency in patients undergoing cancer treatment.

GNH USA supplies Lederfolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lederfolin, a folate analog, is used in oncology and metabolic pathways to address specific therapeutic needs.

Methotrexate rescue: reduces toxicity of high‑dose methotrexate by providing reduced folate to normal cells. 5‑fluorouracil chemotherapy enhancement: increases the cytotoxic effect of 5‑FU in cancer treatment. Folate deficiency: supplies active folate to correct deficiency states.

Adverse reactions to Lederfolin may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Mild fever or chills - Headache - Transient hypotension during infusion

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Persistent hypotension requiring intervention - Acute renal impairment - Hepatic dysfunction or elevated transaminases - Seizures or neurologic events

When using Lederfolin, clinicians should consider several precautionary measures.

Renal function: assess baseline kidney function before administration. Hepatic function: monitor liver enzymes during therapy. Concurrent methotrexate: adjust dosing and timing to avoid excess toxicity. Pregnancy: avoid unless benefits outweigh potential risks. Allergy: discontinue immediately if hypersensitivity signs appear. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lederfolin can interact with other agents used in chemotherapy and supportive care.

Major Interactions (Avoid): - High‑dose methotrexate: may increase folate demand and risk of toxicity. - Antifolates such as pemetrexed: antagonistic effect reducing efficacy. - Live vaccines: reduced immunogenic response.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal function closely. - Hepatotoxic agents (e.g., azathioprine): watch liver enzyme trends. - Drugs affecting plasma protein binding (e.g., warfarin): monitor INR and adjust dose as needed.